Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1958 1
1962 1
1965 1
1967 3
1968 1
1970 2
1971 1
1972 2
1974 2
1975 1
1977 4
1978 1
1979 4
1980 2
1981 1
1982 2
1983 2
1984 1
1985 3
1986 2
1987 1
1988 2
1989 2
1990 2
1991 2
1993 1
1994 2
1997 3
1998 1
1999 2
2000 1
2001 4
2002 2
2004 1
2006 2
2007 1
2008 1
2009 4
2010 1
2011 3
2012 4
2013 7
2014 8
2015 5
2016 11
2017 11
2018 20
2019 14
2020 6
2021 15
2022 7
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: hajek j. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Among authors: hajek j. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Commentary.
Hajek J. Hajek J. J Neurosci Rural Pract. 2013 Jan;4(1):93-4. J Neurosci Rural Pract. 2013. PMID: 23546372 Free PMC article. No abstract available.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. Among authors: hajek j. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
Ebola virus disease and critical illness.
Leligdowicz A, Fischer WA 2nd, Uyeki TM, Fletcher TE, Adhikari NK, Portella G, Lamontagne F, Clement C, Jacob ST, Rubinson L, Vanderschuren A, Hajek J, Murthy S, Ferri M, Crozier I, Ibrahima E, Lamah MC, Schieffelin JS, Brett-Major D, Bausch DG, Shindo N, Chan AK, O'Dempsey T, Mishra S, Jacobs M, Dickson S, Lyon GM 3rd, Fowler RA. Leligdowicz A, et al. Among authors: hajek j. Crit Care. 2016 Jul 29;20(1):217. doi: 10.1186/s13054-016-1325-2. Crit Care. 2016. PMID: 27468829 Free PMC article. Review.
Response to "Selection bias".
Boggild AK, Libman M, Yansouni CP, Freedman DO, Kuhn S, Plourde P, Mirzanejad Y, Hajek J, Chakrabarti S, Geduld J, McCarthy AE, Vincelette J, Ghesquiere W, Kain KC. Boggild AK, et al. Among authors: hajek j. CMAJ. 2017 May 8;189(18):E674. doi: 10.1503/cmaj.732964. CMAJ. 2017. PMID: 28483851 Free PMC article. No abstract available.
A New Alloying Concept for Low-Density Steels.
Hájek J, Nový Z, Kučerová L, Jirková H, Salvetr P, Motyčka P, Hajšman J, Bystřická T. Hájek J, et al. Materials (Basel). 2022 Mar 30;15(7):2539. doi: 10.3390/ma15072539. Materials (Basel). 2022. PMID: 35407871 Free PMC article.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, Ferguson T, Chang YH, Lee JL, Haas N, Sawrycki P, Sarwar N, Gross-Goupil M, Thiery-Vuillemin A, Mahave M, Kimura G, Perini RF, Saretsky TL, Bhattacharya R, Xu L, Powles T. Choueiri TK, et al. Among authors: hajek j. Oncologist. 2024 Feb 2;29(2):142-150. doi: 10.1093/oncolo/oyad231. Oncologist. 2024. PMID: 37589219 Free PMC article. Clinical Trial.
Mechanical Properties of High Carbon Low-Density Steels.
Hájek J, Nový Z, Kučerová L, Jirková H, Donik Č, Jansa Z. Hájek J, et al. Materials (Basel). 2023 May 19;16(10):3852. doi: 10.3390/ma16103852. Materials (Basel). 2023. PMID: 37241479 Free PMC article.
196 results